Patent Thickets Exposed: How Drug Companies Lock Out Generics for Decades After Their Core Patent Expires
AbbVie held Humira’s U.S. market alone for twenty years. Not because it held one brilliant patent, but because it built […]
Branded Generic ROI: The Cold Math Behind a Controversial Strategy
Pharmaceutical executives who pitch branded generics to their boards often face the same question: why pour marketing dollars into a
Branded Generic ROI: The Cold Math Behind a Controversial Strategy Read Post »
Launch First or Lose: How Generic Drug Timing Decides Long-Term Profit
The difference between first place and second place in the generic drug market is not measured in prestige. It is
Launch First or Lose: How Generic Drug Timing Decides Long-Term Profit Read Post »
How Brand-Name Drug Companies Delay Generic Competition: Product Hopping, Patent Thickets, and Market Exclusivity Tactics Explained
AbbVie collected roughly $114 billion in U.S. Humira revenue before the first biosimilar cleared a path to pharmacy shelves. Allergan
Your 2-Year LOE Window Is a 5-Year Death March: The Real Pharmaceutical Patent Cliff Timeline
Every brand team runs the same model. The compound patent expires on a known date. You build a 24-month revenue
Patent Thickets Decoded: How to Find the Real Expiration Date for Blockbuster Drug Patents
The expiration date on a blockbuster drug’s primary patent is almost never the date generic competition arrives. Between that printed
Data Beats Capital: Why the Real Challenger in Pharma IP Is the One Who Knows More
Every few years, a mid-size generic manufacturer files a Paragraph IV certification against a blockbuster drug, gets sued by a
Data Beats Capital: Why the Real Challenger in Pharma IP Is the One Who Knows More Read Post »
Sentiment Analysis in Patent Litigation: How to Predict Pharmaceutical Case Outcomes
Pharmaceutical patent litigation produces more text per dollar at stake than almost any other legal domain. A single Hatch-Waxman case
Sentiment Analysis in Patent Litigation: How to Predict Pharmaceutical Case Outcomes Read Post »
First-to-Market vs. Most-Efficient-to-Market: Why Speed Alone Loses the Generic Drug Race
The conventional wisdom in generic pharmaceuticals is seductive in its simplicity: be first, win big. File first, launch first, collect
